Known For Its Good Chemistry, Du Pont Goes Multidisciplinary

WILMINGTON, DEL.—When Du Pont executives first tried to recruit Mark Pearson back in 1982, he didn't take them seriously. After all, he reasoned, with no corporate history of ground-breaking work in molecular biology, what would the company do with a director of one of the National Cancer Institute's molecular biology laboratories? "Besides," he adds, "they were a chemical company." Not any longer. Within the past five years Du Pont has embarked upon new ventures in electronics, imaging, a

Written bySusan L-J Dickinson
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Not any longer. Within the past five years Du Pont has embarked upon new ventures in electronics, imaging, and even life sciences—for example, protein structures and agricultural science have been added to the company's portfolio alongside the more traditional businesses of polymers, chemical structures, and petroleum. That's why, six years ago, corporate management set out after molecular biologist Pearson. And that's why Du Pont called his bluff.

It seems that even though Pearson didn't take his recruiters seriously, he managed to tell them what he thought a molecular biology outfit ought to look like. "Of course I had my ready-made wish list glued on the inside of my head," he admits. So he "gave them a plan that was interesting and that I thought they wouldn't be interested in pursuing in a million years." Du Pont not only hired him, it granted his entire wish list. Today, as director of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies